Treatment satisfaction and clinical improvement after switch to fingolimod

被引：0
|
作者：
Fox, E.
Edwards, K.
Burch, J. G.
Kim, E.
Pestreich, L.
McCague, K.
Barbato, L.
机构：
[1] MS Clin Cent Texas, Round Rock, TX USA
[2] MS Ctr NE New York, Latham, NY USA
[3] Blue Ridge Res Ctr, Roanoke, VA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2013年 / 260卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P543
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [31] Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau, J.
    Sormani, M. P.
    Signori, A.
    Realmuto, S.
    Baroncini, D.
    Annovazzi, P.
    Signoriello, E.
    Maniscalco, G. T.
    La Gioia, S.
    Cordioli, C.
    Frigeni, B.
    Rasia, S.
    Fenu, G.
    Grasso, R.
    Sartori, A.
    Lanzillo, R.
    Stromillo, M. L.
    Rossi, S.
    Forci, B.
    Cocco, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (10) : 1270 - 1275
  • [32] SWITCHING TO CLOZAPINE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA: THE CLINICAL COURSE, REMISSION, AND AUGMENTATION OF TREATMENT AFTER THE SWITCH
    Senol, Sevin Hun
    Gurcan, Gamze
    Ertugrul, Aygun
    Yagcioglu, Ayse Elif Anil
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S202 - S202
  • [33] Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau, J.
    Sormani, M. P.
    Signori, A.
    Realmuto, S.
    Baroncini, D.
    Annovazzi, P.
    Signoriello, E.
    Maniscalco, G. T.
    La Gioia, S.
    Cordioli, C.
    Frigeni, B.
    Rasia, S.
    Fenu, G.
    Grasso, R.
    Sartori, A.
    Lanzillo, R.
    Cocco, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 911 - 912
  • [34] Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
    Rio, J.
    Tintore, M.
    Sastre-Garriga, J.
    Nos, C.
    Castillo, J.
    Tur, C.
    Comabella, M.
    Montalban, X.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (06) : 899 - 904
  • [35] From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch
    Harrer, Andrea
    Pilz, Georg
    Oppermann, Katrin
    Sageder, Marlene
    Afazel, Shahrzad
    Haschke-Becher, Elisabeth
    Rispens, Theo
    de Vries, Annick
    McCoy, Mark
    Stevanovic, Vlado
    Hitzl, Wolfgang
    Trinka, Eugen
    Kraus, Joeg
    Sellner, Johann
    Wipfler, Peter
    [J]. CLINICAL IMMUNOLOGY, 2017, 176 : 87 - 93
  • [36] CLINICAL SIGNIFICANCE OF THE CARDIOVASCULAR EFFECTS OF FINGOLIMOD TREATMENT IN MULTIPLE SCLEROSIS
    Szeplaki Gabor
    Merkely Bela
    [J]. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (11-12): : 369 - 376
  • [37] Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review
    M. Martinot
    A. Abou-Bacar
    M. Lamothe
    M. Alt Tebacher
    M. Mohseni Zadeh
    F. Dalle
    L. Favennec
    D. Costa
    J. Brunet
    F. Sellal
    [J]. BMC Infectious Diseases, 20
  • [38] Autoimmune Hemolytic Anemia after Treatment with Fingolimod: A Case Report
    Husain, Arif
    Abou Fayssal, Nada
    [J]. NEUROLOGY, 2019, 92 (15)
  • [39] Severe fingolimod rebound syndrome after switching to cladribine treatment
    Coss-Rovirosa, Fernanda
    Salado-Burbano, Jorge
    Casallas-Vanegas, Adriana
    Elizabeth Caire-Herrera, Laura
    Gomez-Figueroa, Enrique
    Flores-Rivera, Jose
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 40
  • [40] Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment
    Lalive, Patrice H.
    Roth, Serge
    Du Pasquier, Renaud
    [J]. NEUROLOGY, 2019, 92 (03) : 151 - 151
12345